Debra Richardson

MD
Professor
Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Debra L. Richardson is Professor of Obstetrics & Gynecology and the Division Director of Gynecologic Oncology at the Stephenson Cancer Center, University of Oklahoma Health Sciences Center. Dr. Richardson is a clinician, surgeon, and also a clinical trialist. She spends 50% of her time leading phase I clinical trials within the SCC early phase drug development unit. She was one of the inagural GOG Foundation Scholars, and a member of the GOG Partners Investigator Council. She is very involved in NRG Oncology, and is a member of the Ovarian and Developmental Therapeutics Committees and the Chair of the Early Phase Trial Oversight Committee. She completed residency at the University of Connecticut, Gynecologic Oncology fellowship at The Ohio State University, and was faculty at UT Southwestern for 8 years. Her research goals are to develop and lead science based and translationally driven early phase trials and move promising treatments into late phase trials. Dr. Richardson enjoys doing medical missions- and has completed one to Nigeria and one to the Phillipines. Her next one will be in Malawi.

2026 Sessions

It is a PARPi and Bevacizumab World – Don’t Fix What Is Not Broken

Presenters will examine the strength and limitations of current evidence supporting standard maintenance regimens alongside evolving data that may refine patient selection and improve outcomes in ovarian cancer. The discussion will address resistance, toxicity, and the future direction of personalized maintenance therapy. Faculty will provide expert insight into how these competing strategies may shape clinical practice.

Review the most recent clinical trial data supporting these strategies, including outcomes across biomarker-defined subgroups. Faculty will discuss optimal patient selection, sequencing considerations, and management of treatment-related toxicities, giving learners a clearer understanding of the role of established maintenance approaches in contemporary ovarian cancer care.

Presenter

Saturday, March 14 4:25–4:45 PM
Room Royal Ballroom 1
Gynecological Cancers

Debra Richardson

MD
Professor
Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Debra L. Richardson is Professor of Obstetrics & Gynecology and the Division Director of Gynecologic Oncology at the Stephenson Cancer Center, University of Oklahoma Health Sciences Center. Dr. Richardson is a clinician, surgeon, and also a clinical trialist. She spends 50% of her time leading phase I clinical trials within the SCC early phase drug development unit. She was one of the inagural GOG Foundation Scholars, and a member of the GOG Partners Investigator Council. She is very involved in NRG Oncology, and is a member of the Ovarian and Developmental Therapeutics Committees and the Chair of the Early Phase Trial Oversight Committee. She completed residency at the University of Connecticut, Gynecologic Oncology fellowship at The Ohio State University, and was faculty at UT Southwestern for 8 years. Her research goals are to develop and lead science based and translationally driven early phase trials and move promising treatments into late phase trials. Dr. Richardson enjoys doing medical missions- and has completed one to Nigeria and one to the Phillipines. Her next one will be in Malawi.

General Session

Front-Line Maintenance Therapy for Ovarian Cancer: It is a PARPi and Bevacizumab World – Don’t Fix What Is Not Broken vs We Can Do Better Than HRD – Opportunities for New Biomarkers and Agents to Improve Outcomes

Presenters will examine the strength and limitations of current evidence supporting standard maintenance regimens alongside evolving data that may refine patient selection and...

  • Moderator
    • Kathleen Moore, MD, MS
  • Presenter
    • Debra Richardson, MD
    • Angeles Secord, MD, MHSc
Gynecological Cancers

It is a PARPi and Bevacizumab World – Don’t Fix What Is Not Broken

Presenters will examine the strength and limitations of current evidence supporting standard maintenance regimens alongside evolving data that may refine patient selection and improve outcomes in ovarian cancer. The discussion will address resistance, toxicity, and the future direction of personalized maintenance therapy. Faculty will provide expert insight into how these competing strategies may shape clinical practice.

Review the most recent clinical trial data supporting these strategies, including outcomes across biomarker-defined subgroups. Faculty will discuss optimal patient selection, sequencing considerations, and management of treatment-related toxicities, giving learners a clearer understanding of the role of established maintenance approaches in contemporary ovarian cancer care.

Presenter

Saturday, March 14 4:25–4:45 PM
Room Royal Ballroom 1
Gynecological Cancers

Debra Richardson

MD
Professor
Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Debra L. Richardson is Professor of Obstetrics & Gynecology and the Division Director of Gynecologic Oncology at the Stephenson Cancer Center, University of Oklahoma Health Sciences Center. Dr. Richardson is a clinician, surgeon, and also a clinical trialist. She spends 50% of her time leading phase I clinical trials within the SCC early phase drug development unit. She was one of the inagural GOG Foundation Scholars, and a member of the GOG Partners Investigator Council. She is very involved in NRG Oncology, and is a member of the Ovarian and Developmental Therapeutics Committees and the Chair of the Early Phase Trial Oversight Committee. She completed residency at the University of Connecticut, Gynecologic Oncology fellowship at The Ohio State University, and was faculty at UT Southwestern for 8 years. Her research goals are to develop and lead science based and translationally driven early phase trials and move promising treatments into late phase trials. Dr. Richardson enjoys doing medical missions- and has completed one to Nigeria and one to the Phillipines. Her next one will be in Malawi.

We Can Do Better Than HRD – Opportunities for New Biomarkers and Agents to Improve Outcomes

Presenters will examine the strength and limitations of current evidence supporting standard maintenance regimens alongside evolving data that may refine patient selection and improve outcomes in ovarian cancer. The discussion will address resistance, toxicity, and the future direction of personalized maintenance therapy. Faculty will provide expert insight into how these competing strategies may shape clinical practice.

Explore emerging biomarkers and novel therapeutic agents shaping frontline maintenance strategies for ovarian cancer. Faculty will review evolving evidence on molecular and genomic markers that may better predict benefit and guide personalized maintenance therapy. The discussion will highlight investigational agents, mechanisms of resistance, and how these advances may complement or challenge current standards of care.

Presenter

Saturday, March 14 4:45–5:05 PM
Room Royal Ballroom 1
Gynecological Cancers

Angeles Secord

MD, MHSc
Professor
Duke Cancer Institute

Dr. Angeles Alvarez Secord, M.D., M.H.Sc., is a Professor in the Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Duke University Heath System. She graduated AOA with Honors from the University of Washington School of Medicine in Seattle, Washington. Dr. Secord completed her residency in Obstetrics and Gynecology and her fellowship in Gynecologic Oncology at the Duke University Medical Center in Durham, North Carolina. Upon completing her fellowship in 2001, she joined the Division of Gynecologic Oncology at Duke. She is currently the Director of Gynecologic Oncology Clinical Trials, the Associate Director of Clinical Research, Gynecology Oncology, and one of the Principal Investigators for NRG Oncology at the Duke Cancer Institute. Dr. Secord has served as a board member for several professional organizations including Society of Gynecologic Oncology (SGO), GOG Foundation, and American Association of Gynecology and Obstetrics Foundation (AAOGF). She is passionate about mentoring the next generation of investigators and previously served as the AAOGF Scholar Committee Chair, and currently serves as the NRG Oncology Investigator Career Development Subcommittee co-Chair and the GOG Foundation Education and Mentoring Chair. Her life experience inspired her motto, “Empower through Teamwork", and fostering synergistic collaboration to help people with gynecologic cancers live longer and better lives.

Back to top